These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17851194)

  • 1. Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs.
    Ballard C; Sorensen S; Sharp S
    J Alzheimers Dis; 2007 Aug; 12(1):53-9. PubMed ID: 17851194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
    Versijpt J
    Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
    Wimo A
    Drugs Aging; 2004; 21(5):279-95. PubMed ID: 15040756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
    Pfeil AM; Kressig RW; Szucs TD
    Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK.
    Zala D; Chan D; McCrone P
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):307-315. PubMed ID: 28612928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic consequences of Alzheimer's disease in the context of new drug developments.
    Knapp M; Wilkinson D; Wigglesworth R
    Int J Geriatr Psychiatry; 1998 Aug; 13(8):531-43. PubMed ID: 9733334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.
    Jönsson L
    Pharmacoeconomics; 2003; 21(14):1025-37. PubMed ID: 13129415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 13. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.
    Caro JJ; Salas M; Ward A; Getsios D; Mehnert A;
    Dement Geriatr Cogn Disord; 2002; 14(2):84-9. PubMed ID: 12145455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
    Gustavsson A; Van Der Putt R; Jönsson L; McShane R
    Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?
    Getsios D; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2007; 25(12):997-1006. PubMed ID: 18047386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Bosanquet N; Yeates A
    Pharmacoeconomics; 2006; 24(6):623-5; author reply 625-6. PubMed ID: 16761908
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.